A detailed history of Charles Schwab Investment Management Inc transactions in Tyra Biosciences, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 173,737 shares of TYRA stock, worth $2.67 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
173,737
Previous 169,945 2.23%
Holding current value
$2.67 Million
Previous $2.72 Million 50.31%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$16.7 - $24.36 $63,326 - $92,373
3,792 Added 2.23%
173,737 $4.08 Million
Q2 2024

Aug 12, 2024

BUY
$14.45 - $20.22 $256,241 - $358,561
17,733 Added 11.65%
169,945 $2.72 Million
Q1 2024

May 08, 2024

BUY
$11.61 - $20.0 $483,846 - $833,500
41,675 Added 37.7%
152,212 $2.5 Million
Q4 2023

Feb 06, 2024

BUY
$11.01 - $14.95 $3,556 - $4,828
323 Added 0.29%
110,537 $1.53 Million
Q3 2023

Nov 08, 2023

BUY
$13.15 - $16.08 $73,074 - $89,356
5,557 Added 5.31%
110,214 $1.52 Million
Q2 2023

Aug 09, 2023

BUY
$11.99 - $17.51 $27,421 - $40,045
2,287 Added 2.23%
104,657 $1.78 Million
Q1 2023

May 11, 2023

BUY
$6.85 - $16.22 $26,488 - $62,722
3,867 Added 3.93%
102,370 $1.65 Million
Q4 2022

Feb 13, 2023

BUY
$5.68 - $8.81 $13,223 - $20,509
2,328 Added 2.42%
98,503 $748,000
Q3 2022

Nov 14, 2022

BUY
$6.61 - $12.42 $98,317 - $184,735
14,874 Added 18.29%
96,175 $846,000
Q2 2022

Aug 15, 2022

BUY
$5.26 - $11.19 $4,444 - $9,455
845 Added 1.05%
81,301 $582,000
Q1 2022

May 13, 2022

BUY
$10.03 - $14.09 $11,123 - $15,625
1,109 Added 1.4%
80,456 $861,000
Q4 2021

Feb 11, 2022

BUY
$12.23 - $31.35 $970,413 - $2.49 Million
79,347 New
79,347 $1.12 Million

Others Institutions Holding TYRA

About Tyra Biosciences, Inc.


  • Ticker TYRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,973,600
  • Market Cap $646M
  • Description
  • Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The comp...
More about TYRA
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.